Keywords: roche, xeloda, gains, eu, ok, colon, cancer
Roche's Xeloda gains EU OK for colon cancer
Article | 11 April 2005
The European Commission has approved Swiss drugmaker Roche's innovative oral chemotherapy Xeloda (capecitabine) for use as an adjuvant therapy (post-surgery) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
